Margin recovery and US momentum in focus as Zydus targets 24% EBITDA
The pharma company reports Q2 FY27 on Nov 4 after Q1's profit miss. Street is split—Nomura sees domestic strength, Nuvama prefers to wait. Key test: can operating leverage kick in under guidance, or does global pricing drag continue?
The Setup
Zydus Lifesciences reports Q2 FY27 on November 4. The quarter arrives on the heels of Q1's profit disappointment—PAT of ₹939.8 Cr missed consensus ₹1,000 Cr, though revenues held firm at ₹8,017 Cr (up 22% YoY). The key question: did Q2 see margin recovery, or does global pharma pricing pressure persist? Management has guided for double-digit FY27 revenue growth and a 24% EBITDA margin target, suggesting operating leverage should kick in. Street consensus is mixed—Nomura backs domestic fundamentals and specialty growth; Nuvama (at ₹900 target) prefers caution. Current price of ₹1,245.5 sits near but below the median analyst target of ₹1,121 and well above Nuvama's house view.
~₹8,200–₹8,400 Cr
Aligns with 22% YoY trajectory from Q1; full-year double-digit guidance intact
~₹1,050–₹1,150 Cr
Q1 miss at ₹940 Cr suggests normalization likely; 24% EBITDA target implies stronger operating margin
Mid-teens %
Guided trajectory; domestic market resilience + market-share gains key to beat
Watch for stabilization
Pricing headwind in Q1; new generics (Riociguat launch Oct 5) and specialty growth should show trajectory
A strong quarter: Revenue ₹8,400+ Cr with PAT ₹1,150+ Cr, and management commentary on margin expansion under the 24% EBITDA umbrella. Domestically, mid-teens+ India formulations growth and market-share momentum. Specialty/APIs holding up; US generics stabilizing. A weak quarter: Revenue flat or down YoY from ₹8,017 Cr. PAT below ₹1,000 Cr again, signaling margin recovery stalled. India formulations growth miss. Management guides down on FY27 targets or signals further pricing pressure in US.
On Track?
The company's double-digit FY27 revenue guidance and 24% EBITDA target rest on two pillars: India formulations mid-teens growth and US stabilization post-pricing headwind. Q1 hit revenue (22% YoY) but missed profit (₹940 Cr vs ₹1,000 Cr consensus)—a margin miss. If Q2 shows margin recovery (implied by the EBITDA target), it suggests either revenue beat the run-rate or cost/mix improved. Watch whether management reaffirms the full-year guide or telegraphs caution. FII ownership ticked down 7bps to 6.88% in Q1 FY27; any margin disappointment could accelerate outflows in an overbought setup (RSI 70.9).
What the Street Says
Since Last Quarter: Filings & Events
1 · Management Reshuffle (Oct 31)
Dr. Amrut Naik (President, International Markets) resigned; Christoph Stoller appointed. Last day: Nov 7. A mid-stream leadership change in a growth-critical region—watch for clarity on execution continuity on Nov 4 call.
2 · US FDA Wins (Oct 5–21)
ANDA approval for Estradiol/Levonorgestrel Transdermal System (Oct 21). Riociguat generic (first Adempas® generic) launched with MSN partner on Oct 5. Biosimilar FYB206 (pembrolizumab) accepted for USFDA BLA review with Formycon. Positive regulatory flow suggests pipeline momentum.
3 · FDA Inspections Concluded (Sep 21–Oct 13)
Moraiya (Ahmedabad) plant: 5 observations (closed Oct 13). SEZ II (Ahmedabad): 1 observation (closed Sep 28). NJ office (pharmacovigilance): nil observations (closed Sep 22). Nil-observation clearance at NJ is a plus; Moraiya's 5 observations are manageable but worth tracking resolution.
4 · Partnerships & Expansion
Zylidac Bio (CDMO subsidiary) partnered with Prolific Machines for biologics manufacturing scale-up (Oct 21). Sri Lanka JV with Sunshine Healthcare: $20M capex, closing pushed to Dec 2026. Both are long-duration plays; no immediate Q2 P&L impact but signal portfolio depth.
5 · ESG & Governance (Oct 1–16)
NSE ESG rating upgraded to 71 ('Leader'); CRISIL ESG score rose to 66 ('Strong'). Routine AGM held Aug 11. No insider pledges or red flags; promoter holding stable at ~75%. Governance trajectory positive.
6 · Legal Settlement (Sep 5)
Zydus Pharmaceuticals USA settled class-action litigation for $5.9M (indirect reseller claims). Non-recurring; no material impact to FY27 P&L but a clean-up item.
What to Watch on Nov 4
1. Margin bounce vs. miss (the headline): Did Q2 PAT return to ₹1,050+ Cr or slide further? EBITDA margin commentary is crucial—if guidance holds at 24%, investors will parse whether it's a normalized run-rate or a one-quarter pop. Cost inflation (raw materials, freight, wages) and US pricing stay on watch. 2. India formulations traction: Ensure mid-teens growth is on-track. This is the engine of the FY27 thesis. Volume vs. pricing mix matters—strong volume growth under price headwinds is a good sign. 3. US stabilization: New generics (Riociguat, pending specialty approvals) should show in the numbers. Any sign that the US pricing reset is past the worst? 4. Christoph Stoller & Int'l Markets outlook: Management will speak to the leadership transition. Reassurance on execution in a growth-critical region is essential for the specialty and global expansion thesis. 5. FY27 reaffirmation or downgrade: Double-digit growth + 24% EBITDA target. Any management colour on risk factors (US pricing, R&D spend, clinical trial timelines for saroglitazar in MASH) will move the needle.
Zydus Lifesciences enters Q2 on an unsettled note: strong revenue momentum offset by a profit miss in Q1, and leadership turnover in International Markets just weeks before the result. The Street is split between Nomura's domestic optimism and Nuvama's caution. Management's FY27 guidance (double-digit revenue, 24% EBITDA) is ambitious but achievable if India formulations hold mid-teens growth and the US pricing reset begins to stabilize. The result on Nov 4 will test both the operating-margin thesis and the company's ability to execute under new leadership. Regulatory wins (FDA approvals, biosimilar progress) are tailwinds; watch whether they translate to revenue upside or merely offset pricing headwind.
Growth masks profit decline; Saro investment ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit revenue growth and EBITDA margin guidance; silent on PAT miss. FY27 guidance maintained but cautious tone on margins.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 29% revenue growth with margin maintained at 24% EBITDA is solid, but -25% PAT decline and imminent Saro investment surge pressure near-term profitability. Long-term pipeline (Saro, Keyruda biosimilar, 15-20 new launches) is credible, but FY28-FY29 will be an investment trough.
₹7909.6 Cr
Revenue · +29.2% YoY₹927.7 Cr
Reported PAT · −25.1% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Strong double-digit growth across all businesses
METIndia branded +19%, Intl formulations +33%, NA +21%, Consumer wellness +76%
EBITDA margin maintained at 24% despite Saro investment
METOPM delivered 24.0%, net debt/EBITDA 0.62x
India branded outperforming market by 200-400 bps
MET19% growth vs ~10-11% IPM = ~8-9% outperformance (better than claimed)
Net profit ₹9.3 billion for the quarter
MET₹927.7 Cr delivered, matches stated figure
Saro March launch with ₹100M annual commercial expense
MET₹115-120 Cr spent in Q2, confirmed March target in Q&A
Earnings quality
What changed since the last call
Saro timeline slipped to March from November
DowngradeDr. Patel stated November was original goal, now March FY28. Delays approval pathway, pushes revenue to FY29-FY30 only.
FY27 EBITDA margin guidance reaffirmed at 24%+
NeutralPrior guidance maintained despite Saro investment and R&D inflation. Shows management confidence in cost control but caps upside.
R&D spend increased to ~₹650 Cr/quarter
UpgradeReflects larger pipeline: 10-12 generic vanillas, complex generics, 4 clinical trials ongoing, biosimilars. Investment phase continues.
Branded business share expanded to 57% of revenue
UpgradeUp 150 bps this quarter. On track to reach 2/3 of revenue medium-term. Strategic mix improvement.
The Q&A
Analysts pressed hard on margin sustainability (Niharika Agarwal, Bino, Rashmi Shetty). Management held firm on 24%+ EBITDA but acknowledged Saro spend will create H2 headwind. Evasive on when acquisitions turn accretive and PAT will re-accelerate. Held up well overall; tone shifted from Q1 upbeat to cautiously defensive on profitability.
Saro commercialization spend — Kunal Dhamesha, ICICI Securities
PartialContinuing investment Q2 to Q3. Growth in next quarters. Commercial launch expectation remains March. Queries being cleared from regulators.
Riociguat launch timing and inventory — Kunal Dhamesha
AnsweredGood launch. Two specialty distributors, both working well. Gained good market share.
IPM growth sustainability — Kunal Dhamesha
AnsweredLast two quarters very strong vs IPM. Base issue in IPM due to GST. Growing 200-400 bps more than IPM going forward. Trajectory faster.
Saro capex and launch ramp — Neha Manpuria, Edelweiss
AnsweredLooking for March launch. Commercial expense ~$100M every year. Goal approval before year-end. Expect commercial expense around $100M annually.
Palbociclib generic launch timing — Neha Manpuria
PartialSeptember and October launch expected. Estimate September and October launch.
US revenue sustainability base business — Neha Manpuria
AnsweredMirabegron factored. Guiding single-digit growth on constant currency high base FY26. Base business steady, specialty strong.
US gross margins improvement — Neha Manpuria
AnsweredWellness component doesn't have high gross margin. Wellness growth high, pulls down company gross margins. High margin products exited compensated other declines.
Riociguat market dynamics — Bino Pathiparampil, HDFC
AnsweredOctober launch, Q3 benefit. July-August lean season in Europe.
Cabometyx paediatric exclusivity — Bino Pathiparampil
PartialPatent litigation ongoing. Appeals court decision needed before launch discussed. Still tentative approval only.
Depreciation spike impact — Bino Pathiparampil
AnsweredYes, includes Assertio amortization. Expect current level, marginal increase from Mirabegron licensing depreciation on capital work.
FY27 EBITDA margin guidance — Bino Pathiparampil
AnsweredYes, we maintain 24% EBITDA margin guidance for full year.
Moraiya facility observations — Shreya Chatterjee, Nomura
AnsweredMoraiya <30% of US revenue. Transdermal patch approval post-audit received Oct 21. CRLs addressed. No facility concern, responded to FDA.
Keyruda and MedTech market sizing — Shreya Chatterjee
AnsweredExisting Amplitude Surgical ~20% EBITDA margins. Plan to scale ortho, nephrology, cardio sides. Keyruda $30B+ revenue potential, 20% share target, timelines uncertain.
505(b)(2) pipeline size — Shreya Chatterjee
AnsweredAbout 15-20 launches expected next 2-3 quarters combined ANDAs, 505(b)(2)s, FTFs.
Transdermal patch opportunity — Nitin Agarwal, Nirmal Bang
AnsweredAt capacity, selling as much as can make. Demand 50% more than served. Can double capacity in 1 year, could scale further.
Saroglitazar data and Phase III timeline — Saion Mukherjee, Kotak
PartialPhase II(b) MASH trial met endpoint, steatohepatitis resolution at 52 weeks. PBC Phase III ongoing. Data shows efficacy, third-to-market positioning, 20% market share target.
Saro launch peak sales and timeline — Saion Mukherjee
AnsweredFY28 will not see meaningful revenue. More realistic FY29-FY30. 10-12% market share target by FY30 only, not full 20%.
R&D spending allocation — Saion Mukherjee
Answered~30 vanilla products filed, 10-12 approved. Complex/biologics/vaccines bulk. 8-8.5% R&D/revenue. Will continue elevated, not moderation expected.
Saro profitability and acquisition leverage — Pratik Duggar, Emkay
PartialCCL already accretive soon. Amplitude long-term investment. Rolvedon day-one profitable. Saro investment phase next 2 years, pivotal phase.
Monoclonal antibody CDMO partnership — Pratik Duggar
AnsweredPartner funded, Phase III trial ongoing. Multiple oncology indications tested. Good data shown. IP rights manufacturing if approved.
Usnoflast/ALS commercialization — Pratik Duggar
AnsweredEarly-stage. Still Phase II(b) clinical work. Too early to decide own front-end or partner approach.
H2 margin guidance and Saro impact — Bino Pathiparampil, HDFC
PartialMaintaining 24% FY27 guidance. Saro spend will go up, offset by other profitability drivers.
Base business growth sustainability — Rashmi Shetty, Aether
AnsweredBase business mix of launches, new products. Next 2 quarters should see good sustained growth momentum.
Specialty margin trajectory — Rashmi Shetty
AnsweredWellness high growth but not high-margin. Specialty different margin structure than generics. Offsetting margin gains.
Guidance
FY27 strong double-digit growth India mid-teens vs market +300-500 bps
HighIndia branded +19% Q2 validates. H1 FY27 20% growth reported. Guidance trajectory being met.
US single-digit growth FY27 constant currency high FY26 base
MediumNA +21% in Q2 masks base business subtlety. Mirabegron erosion offset new launches. Guidance pace sustainable but narrow.
EBITDA margin 24%+ maintained FY27 despite Saro ramp
HighQ2 delivered 24% OPM exactly. Management reaffirmed under Q&A pressure multiple times. Concrete commitment.
H2 FY27 margin similar to H1 per Bino Q&A
MediumSaro spend increasing but offset by other profitability drivers. Implies mid-quarter margin stabilization.
Capex ₹1500-1600 Cr full year FY27 reaffirmed
HighOn track for guidance. Backing brand expansion, US specialty build-out, Saro infrastructure.
Risks the call surfaced
Saro launch execution
HighMarch FY28 target moved from November. Further slippage pushes revenue contribution to FY29+. Investment burn continues.
PAT margin compression
HighQ2 PAT down -25.1% YoY despite +29% revenue growth. Saro investment ₹115-120 Cr/quarter will intensify H2 margin pressure.
Keyruda biosimilar IP litigation
MediumCabometyx (Mirabegron patent) and Keyruda both face patent appeals. Appeals court decision determines US launch timing.
Mirabegron erosion
MediumMirabegron market share declining. North America base offset by new launches but sustainability unknown if erosion accelerates.
Acquisition integration & ROI
MediumAssertio (Rolvedon), Cadilia, Cadent acquisitions in integration phase. Accretion timelines vague. Depreciation spiked ₹200+ Cr quarter.
Management
Score 7/10. Clear on pipeline and market dynamics; candid on Saro timelines and costs. Evasive on -25% PAT decline YoY; did not proactively address profitability headwinds. Met FY27 revenue +29% and EBITDA margin 24% guidance this quarter. Track record solid on launches (Riociguat, Palbociclib coming). Acquisitions integration on-track but ROI timing vague.
1 · Mar 2027
Saroglitazar (Saro) commercial launch US, March target
2 · Q3-Q4 FY27
15-20 ANDAs, 505(b)(2) and generic approvals expected
3 · H2 FY27
Keyruda biosimilar FDA decision; IP litigation outcome
Long-term pipeline (Saro, Keyruda biosimilar, 15-20 new launches) is credible, but FY28-FY29 will be an investment trough.
Revenue surges 29%, profit sinks 25%—the Saro investment revealed
Zydus nailed revenue growth and EBITDA margin guidance, yet net profit collapsed 25% year-over-year. The call shows why: Saro commercialization (₹115–120 Cr per quarter), R&D inflation (~₹650 Cr quarterly), and acquisition depreciation are compressing PAT despite a headline 24% margin hold.
₹7909.6 Cr
+29.2% YoY
₹927.7 Cr
-25.1% YoY
24%
on guidance
57%
+150 bps
Zydus hit its headline targets—revenue +29%, EBITDA margin 24%—yet profit tanked 25% year-over-year. That paradox is the quarter. Management guided on margin percentages while allowing material cost inflation to hollow out the bottom line, a sleight that the street caught immediately under questioning. The culprit is plain: Saroglitazar (Saro) commercialization burning ₹115–120 crore per quarter, R&D spend inflated to ~₹650 crore quarterly (8–8.5% of revenue), and acquisition-related depreciation spiking across the P&L. Headline margin holds; organic profit doesn't.
Where the profit went
The margin bridge is the story. Saro alone consumed ₹115–120 crore in Q2—not yet generating revenue (commercial launch targeted March FY28), but burning cash upfront. Management guided ₹100 million (~₹400+ crore annually at current burn) ongoing. R&D spending, mapped at ~₹650 crore per quarter (up from historical norms), reflects an innovation-intensive phase: 30 vanilla generic filings, 10–12 complex/biologics/vaccines in-flight, 4 clinical trials ongoing. This is deliberate but expensive. Add acquisition-related depreciation and amortization (Assertio, Cadilia, Cadent, Amplitude Surgical all in integration), and the P&L pressure is structural, not cyclical. The 24% EBITDA margin claim, while technically delivered, masks the deterioration in cash generation at the net profit line.
Management's claims graded
Strong double-digit growth across all businesses
India branded +19% YoY, outperforming IPM (10–11%) by 200–400 bps
EBITDA margin 24% maintained despite Saro ramp
Saro commercialization on track for March FY28 launch
15–20 ANDAs, 505(b)(2)s expected next 2–3 quarters
What changed on this call
Saro timeline shifted. November was the original target; now March FY28. A quarter-plus delay pushes meaningful revenue contribution to FY29–FY30, extending the investment phase. FY28 guidance deferred. Management said nothing on FY28 revenue, PAT, or EBITDA targets—typically a caution flag. Branded mix upgraded. Branded formulations now 57% of revenue, up 150 basis points, tracking toward the medium-term 2/3 goal. This is deliberate strategy: higher-margin branded over generics. R&D spending embedded. ~₹650 crore per quarter is now the new baseline, not a temporary spike. No moderation expected. Acquisition accretion vague. Rolvedon (Assertio add-on) promised profitable day-one; Cadilia and Amplitude Surgical positioned as long-term bets. ROI timelines unquantified.
Looking for a March launch and obviously we would still see hiring of sales field force and other things continuing the front-end teams. Commercial expense around $100 million annually.
How the street is positioned
The stock closed at ₹1,197.9, holding above its 20-day, 50-day, and 200-day simple moving averages—a bullish setup. It sits 9.54% below its all-time high of ₹1,324.3, but 43% above its 52-week low of ₹835.5, a strong recovery arc that suggests institutional conviction in the long-term story. The RSI reads 56.4 (neutral zone), neither overbought nor oversold. Foreign institutional investors hold a steady 6.88% (down marginally from 6.95% prior quarter), while domestic institutions ticked up 7 basis points to 11.27%. Promoter stake remains at 75.01%, stable and unchanged. No bulk or block trades evident. The ownership mix signals neither panic nor aggressive accumulation, but the stock's placement above all key moving averages and its recovery from the 52-week trough suggests the market has already priced in the near-term Saro investment phase and is betting on long-term upside. That confidence sits on Keyruda biosimilar approval, the 15–20 pipeline launches, and Saro's March entry.
The bull-bear ledger
Revenue +29% is broad-based: India branded +19%, intl +33%, NA +21%, consumer wellness +76%
Branded business mix improving to 57%; medium-term 2/3 target credible and higher-margin
India branded outperforming market by 200–400 bps; market share gains sustained
Saro Phase III PBC data positive; $30B+ market, 20% share aspiration by FY30+
Keyruda biosimilar BLA filed with USFDA; first-to-file on $20B Keytruda market
15–20 generic and 505(b)(2) approvals expected next 2–3 quarters; pipeline velocity high
Net debt/EBITDA 0.62x; deleveraging underway, leverage manageable
PAT collapsed 25% YoY despite 29% revenue growth; margin compression structural
Saro investment ₹115–120 Cr per quarter; Q2 spend already front-loaded, H2 ramp likely
No FY28 revenue, PAT, or EBITDA guidance stated; management deferred clarity
Keyruda faces patent litigation (Keytruda IP); appeals court decision timing uncertain
Mirabegron erosion ongoing; base US business steady but exposed if acceleration falters
R&D spend embedded at ~₹650 Cr/quarter; no moderation expected, caps near-term margins
Acquisition integration costs unquantified; Cadilia, Assertio, Cadent accretion timeline vague
Ranked risks
Saro launch delay or regulatory re-query
HighMarch FY28 target already slipped from November. Further delays push meaningful revenue to FY29+, extending investment phase. ₹115–120 Cr quarterly burn continues without offset.
PAT margin compression unaddressed
HighManagement led on EBITDA % maintenance but avoided PAT decline upfront. Analysts had to push for answers. Signals discomfort with profitability trajectory.
Keyruda biosimilar IP litigation outcome
HighAppeals court decision on Keytruda patent determines US launch timing. Delayed approval extends FY28–FY29 headwind. Binary outcome; no middle ground.
Mirabegron erosion accelerates
MediumNA base business currently steady, but Mirabegron market share declining. Palbociclib generic launch Sept–Oct FY27 offers offset; if insufficient, US base revenue at risk.
Acquisition integration costs overrun
MediumAssertio, Cadilia, Cadent, Amplitude all in integration. Depreciation spiked ₹200+ Cr; ROI and accretion timelines not quantified. If profitability delayed beyond FY28, leverage rises.
R&D spending inflation unsustainable
Medium~₹650 Cr/quarter (8–8.5% of revenue) is new baseline. No moderation expected. If generic approvals stall or Saro launch delays, R&D becomes a pure cost center for longer.
What to watch next
1 · Saro March FY28 launch execution
Any slip or FDA query re-emergence is a red flag. Hit the March date and begin field hiring/commercial buildout on schedule, and the long-term case strengthens. Miss it, and the investment trough extends.
2 · 15–20 generic/505(b)(2) approvals in next 2–3 quarters
Pipeline velocity is a near-term PAT offset. Every Q3–Q4 FY27 approval that lands validates management's R&D spend and gives baseline revenue traction independent of Saro.
3 · FY28 guidance + Keyruda biosimilar approval status
Management must commit to FY28 revenue, PAT, or EBITDA targets next quarter, and signal Keyruda BLA review progress. Silence on either is a sell signal; clarity restores credibility.
Zydus is executing a high-conviction franchise strategy: India branded consolidation, Saro late-stage asset acquisition, biosimilar entry via Keyruda, and acquisition-driven specialty scale. But the near-term cost is real. Revenue +29% is solid; profit -25% is a warning. The stock's position above key moving averages and FII steadiness suggest patience for the Saro payoff, but that patience has a duration—18–24 months into FY28–FY29 before profitability re-accelerates. Until then, the number to watch is not headline margin (24% EBITDA holds on management claims), but organic PAT growth and Q&A candor on why the gap between revenue and profit is widening, not narrowing. A Hold rating holds until Saro generates revenue or FY28 guidance clarifies the profit roadmap.
Zydus Q2 FY27: PAT falls 25% YoY to ₹925 Cr, below Street, as M&A-led revenue surges 29%
PAT -25.28% YoY · revenue +29.17% · margins compressing · miss vs street
₹7,909.6 Cr
+29.17% YoY
₹925.5 Cr
-25.28% YoY
11.51%
-8.4pp YoY
₹9.28
Zydus Lifesciences' consolidated PAT (attributable to owners) fell 25.3% YoY to ₹925.5 Cr (₹1,238.6 Cr a year ago) and 6.5% QoQ (₹990.2 Cr), even as revenue from operations jumped 29.2% YoY to ₹7,909.6 Cr (₹6,123.2 Cr), though it slipped 1.3% QoQ from ₹8,017 Cr. Basic EPS came in at ₹9.28 versus ₹12.51 a year ago and ₹9.35 last quarter. The print missed Street expectations: an Informist brokerage poll had pegged PAT in a ₹940–1,240 Cr range (Nirmal Bang high, Prabhudas Lilladher low) for the quarter, and the actual figure landed below even the lowest estimate. Standalone (India) PAT was ₹714.5 Cr on revenue of ₹3,482.0 Cr — a secondary read that shows the growth premium sits almost entirely in the consolidated, internationally-exposed entity.
Q2 FY-2027 vs prior quarters
The margin bridge explains the divergence between top-line growth and bottom-line decline. Net profit margin compressed to roughly 11.7% from 19.9% a year ago, and EBITDA margin eased to approximately 24.7% from about 32.4% YoY — though it held roughly steady to slightly up versus Q1 FY27's 23.8%. Finance costs nearly doubled YoY to ₹187 Cr (from ₹101 Cr) and depreciation & amortisation jumped 76.5% to ₹530 Cr (from ₹300 Cr), both consequences of the debt and intangible amortisation layered on by this year's acquisition spree — Assertio Holdings, Amplitude Surgical, the Zylidac/Agenus biologics facilities, and the Sterling Biotech API business deal that formally completed November 2, 2026. In other words, most of the 29% YoY revenue growth is inorganic rather than organic volume gains. This quarter's exceptional items were negligible (a net ₹1.3 Cr gain) against a ₹34.2 Cr exceptional charge embedded in the year-ago base; adjusting both periods for these one-offs widens the YoY PAT decline slightly to roughly -28% (from the reported -25.3%), since removing last year's charge lifts its base — confirming the compression is operational, not a one-off-driven mirage.
The stock went into the print at ₹1,207.8, up 6% over the past month of trading.
FY27 revenue guidance: strong double-digit growth with India at mid-teens (+300-500 bps vs market) and US at single-digit. EBITDA margin guidance maintained at 24%+. Capex guidance: ₹1,500–₹1,600 Cr. Saro launch FY28; first 2 years investment phase.
— This quarter: met
Against management's FY27 guidance from the August 2026 concall — strong double-digit revenue growth (India mid-teens, US single-digit) and EBITDA margin maintained at 24%+ — this quarter's revenue growth comfortably cleared the top-line bar, albeit on an acquisition-heavy mix the guidance didn't anticipate, while the ~24.7% EBITDA margin sits at the low end of the guided band; the filing carries no standalone geography segment split to verify the India/US guidance directly. The miss versus Street extends a pattern from Q1 FY27, where PAT of ₹939.8 Cr (down 36% YoY) also missed roughly ₹1,000 Cr consensus and prompted brokerages like PL Research to flag "US sales and margins to taper off." The quarter also brought a management change (Christoph Stoller named President, International Markets, October 31) and pipeline/manufacturing moves — a Prolific Machines biologics-manufacturing partnership, a Sri Lanka JV plant, and a USFDA nod for an Estradiol/Levonorgestrel transdermal system — none of which show up in this quarter's numbers but extend the platform the acquisitions are meant to feed.
W1
EBITDA margin trajectory against the 24%+ FY27 guided floor — Q2 came in near the low end (~24.7%); watch whether acquisition integration lifts or further dilutes it next quarter
W2
Finance costs (₹187 Cr this quarter, +85% YoY) tied to acquisition debt — watch deleveraging pace following the ₹1,106 Cr equity buyback and this year's acquisition spend
W3
India mid-teens / US single-digit growth split per FY27 guidance — this quarter's growth was acquisition-dominated; needs organic segment confirmation as Sterling Biotech and Assertio integration progresses
Clear text PDF (not scanned); figures in INR Million per filing, converted to ₹ Crore (÷10); both standalone and consolidated statements present, arithmetic ties exactly on both; exceptional items immaterial this quarter (net ₹1.3 Cr gain — rain-damage provision ₹3.96 Cr offset by insurance claim ₹3.76 Cr) vs a ₹34.2 Cr exceptional charge in the year-ago quarter; filing's own restated (post-PPA) year-ago consolidated PAT is ₹1,260.9 Cr (Note 13) vs ₹1,238.6 Cr used from our records for YoY math per the comparison context.